Loading...
Loading...
CytRx Corporation
CYTR, a biopharmaceutical company specializing in
oncology, announced that favorable data from its Phase 1b/2 clinical trial
with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly
INNO-206) in patients with advanced soft tissue sarcoma was presented today at
the Sarcoma Poster-Discussion Session (Hall H) at the ESMO (European Society
of Medical Oncology) 2012 Congress in Vienna, Austria. The presentation,
entitled “INNO-206 (aldoxorubicin) Is An Active Drug For Relapsed Soft Tissue
Sarcoma,” was given by renowned sarcoma expert Sant P. Chawla, M.D., Director
of the Sarcoma Oncology Center in Santa Monica, CA.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in